$GRCE SEC Filings

Filed On	Filing
26 Oct 2026	Form 4: Opaleye Management Inc., 10% owner Bought 21,390 shares ($41.2K) · Bought 66,411 shares ($117K)
21 Oct 2026	Form 4: Opaleye Management Inc., 10% owner Bought 4,256 shares ($8K)
16 Oct 2026	Form 4: Opaleye Management Inc., 10% owner Bought 11,233 shares ($21.7K) · Bought 23,485 shares ($45.7K) · Bought 36,347 shares ($68.8K)
13 Oct 2026	Form 4: Opaleye Management Inc., 10% owner Bought 2,077 shares ($4.19K) · Bought 5,340 shares ($10.9K) · Bought 7,215 shares ($14.6K)
05 Oct 2026	Form 4: Opaleye Management Inc., 10% owner Bought 38,796 shares ($79K) · Bought 20,000 shares ($41.4K) · Bought 1,694 shares ($3.49K)
01 Oct 2026	Form 4: Opaleye Management Inc., 10% owner Bought 7,849 shares ($16.4K)
01 Oct 2026	Form 4/A: Opaleye Management Inc., 10% owner Bought 9,771 shares ($20.5K) · Bought 5,318 shares ($11.2K)
23 Sep 2026	Form 4: Opaleye Management Inc., 10% owner Bought 9,771 shares ($20.5K) · Bought 5,318 shares ($11.2K)
21 Sep 2026	Form 4: Neugeboren Edward, Director Granted 12,200 Stock Option (Right to Buy)
21 Sep 2026	Form 4: Davis A Brian, Director Granted 0 Stock Option (Right to Buy)
21 Sep 2026	Form 4: Kavuru Vimal, Director Granted 12,200 Stock Option (Right to Buy)
21 Sep 2026	Form 4: Kottayil George, Director Granted 12,200 Stock Option (Right to Buy)
18 Sep 2026	8-K: Submission of Matters to a Vote of Security Holders On September 17, 2026, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended,...
10 Sep 2026	Form 4: Opaleye Management Inc., 10% owner Bought 9,393 shares ($19.7K) · Bought 5,836 shares ($12.2K)
10 Sep 2026	Form 4: Kohli Prashant, Director Bought 100,000 shares ($214K)
01 Sep 2026	Form 4: Kumar Amresh, VP Program Management Granted 35,760 Stock Option (Right to Buy)
01 Sep 2026	Form 4: Kohli Prashant, Director Granted 267,160 Stock Option (Right to Buy)
01 Sep 2026	Form 4: Macdonald R. Loch, Chief Medical Officer Granted 54,690 Stock Option (Right to Buy)
01 Sep 2026	Form 4: DelAversano Robert J, Principal Financial Officer Granted 33,660 Stock Option (Right to Buy)
31 Aug 2026	EFFECT

Comments